NCT06701396Phase 3Recruiting

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

Study sponsor: Vanda Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06-30Estimated
Enrollment · participants60Estimated
Source updated2024-11-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.